CARA took a -40% dive earlier this month on news that their "oral osteoarthritis drug helped hip pain but failed to reduce knee discomfort."
The company quickly pointed out that drug is in early development in an attempt to calm the market.
Today we see the sellers easing off and buyers coming back in.
Anybody here follow this story? Whats your take?
Submitted July 12, 2017 at 07:53AM by StockJock-e